Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar;23(3):161-5.
doi: 10.1007/s12471-015-0651-3.

Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users : A position statement on the use of bioresorbable vascular scaffolds in the Netherlands

Affiliations

Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users : A position statement on the use of bioresorbable vascular scaffolds in the Netherlands

Bert Everaert et al. Neth Heart J. 2015 Mar.

Abstract

Percutaneous coronary interventions (PCI) have become a reliable revascularisation option to treat ischaemic coronary artery disease. Drug-eluting stents (DES) are widely used as first choice devices in many procedures due to their established good medium to long term outcomes. These permanent implants, however, do not have any residual function after vascular healing following the PCI. Beyond this initial healing period, metallic stents may induce new problems, resulting in an average rate of 2 % reinterventions per year. To eliminate this potential late limitation of permanent metallic DES, bioresorbable coronary stents or 'vascular scaffolds' (BVS) have been developed. In a parallel publication in this journal, an overview of the current clinical performance of these scaffolds is presented. As these scaffolds are currently CE marked and commercially available in many countries and as clinical evidence is still limited, recommendations for their general usage are needed to allow successful clinical introduction.

PubMed Disclaimer

References

    1. Deb S, Wijeysundera HC, Ko DT. Coronary artery bypass graft surgery vs percutaneous interventions in coronary revascularization: a systematic review. JAMA. 2013;310:2086–95. doi: 10.1001/jama.2013.281718. - DOI - PubMed
    1. Stone GW, Moses JW, Ellis SG. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008. doi: 10.1056/NEJMoa067193. - DOI - PubMed
    1. Simsek C, Magro M, Boersma E. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries. JACC Cardiovasc Interv. 2010;3:1051–8. doi: 10.1016/j.jcin.2010.08.003. - DOI - PubMed
    1. Felix C, Everaert B, Diletti R, et al. Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions. Neth Heart J. 2015. doi:10.1007/s12471-015-0652-2. - PMC - PubMed
    1. NVVC. Introductie nieuwe technieken in de klinische praktijk. NVVC/NVT. 2011.https://www.nvvc.nl/media/files/03_Introductie_nieuwe_interventietechnie....

LinkOut - more resources